Physician profile
Cassandra M Calabrese
NPI 1548550007
$68,842.82
in general payments reported to CMS, 2019-2025
16 companies · $13K in 2025
The $13K reported for 2025 was more than what 91% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,758 · 2020: $2,760 · 2021: $3,462 · 2022: $9,239 · 2023: $30K · 2024: $94.99 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Travel and Lodging: $2,251 · Food and Beverage: $934 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,401.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,932.00 |
| Travel and Lodging | $2,251.19 |
| Food and Beverage | $934.33 |
| Education | $105.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $24,925.93 | 2022-2023 | Evusheld, Saphnelo |
| Genzyme Corporation | $19,944.19 | 2020-2025 | |
| Eli Lilly and Company | $6,465.69 | 2022-2023 | |
| Glaxosmithkline, LLC. | $6,362.28 | 2019 | |
| Invivyd INC | $3,737.50 | 2025 | Pemgarda |
| Regeneron Healthcare Solutions, INC. | $2,786.77 | 2019 | |
| Pfizer INC. | $2,236.37 | 2020-2023 | |
| Astrazeneca Uk Limited | $1,251.02 | 2023 | |
| Abbvie INC. | $470.63 | 2019 | |
| Amgen INC. | $321.19 | 2025 | Uplizna, Krystexxa |
| Horizon Therapeutics Plc | $137.87 | 2019 | |
| Janssen Biotech, INC. | $94.99 | 2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $65.10 | 2022-2023 | |
| Janssen Scientific Affairs, LLC | $30.76 | 2025 | Tremfya |
| Gilead Sciences, INC. | $10.53 | 2023 | Veklury |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $2.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cassandra Calabrese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.